Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CU104 will administer the study drug once a day after a meal”In the company’s words, NCT05907330 on ClinicalTrials.gov
- Tested for
- Ulcerative Colitis
- Main trialPhase 2
- “The study is designed to investigate efficacy and safety of CU104 in patients with moderate to severe ulcerative colitis.”In the company’s words, NCT05907330 on ClinicalTrials.gov
Other drugs for Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Unknown | 28 Feb 2026 | Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026